| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | John T. O'Brien | Q37830687 |
| P2093 | author name string | Sean Colloby | |
| P2860 | cites work | A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease. | Q30708048 |
| Proton magnetic resonance spectroscopy in dementia with Lewy bodies | Q30737448 | ||
| Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group | Q31388180 | ||
| Event-related functional magnetic resonance imaging in Parkinson's disease before and after levodopa | Q32061822 | ||
| HMPAO SPECT in Parkinson's disease before and after levodopa: correlation with dopaminergic responsiveness | Q33731224 | ||
| Statistical parametric mapping with 18F-dopa PET shows bilaterally reduced striatal and nigral dopaminergic function in early Parkinson's disease | Q35451581 | ||
| Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand | Q35468295 | ||
| [(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease | Q35471953 | ||
| Occipital hypoperfusion in Parkinson's disease without dementia: correlation to impaired cortical visual processing | Q35473005 | ||
| [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease | Q36901896 | ||
| Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study | Q42164079 | ||
| Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease | Q42458585 | ||
| [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease | Q43576719 | ||
| Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study | Q43693338 | ||
| Perfusion ECD/SPECT in the characterization of cognitive deficits in Parkinson's disease | Q43696867 | ||
| [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression | Q43820139 | ||
| Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [(18)F]FDG-PET. | Q43827112 | ||
| [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy | Q43827115 | ||
| Beta-CIT-SPECT combined with UPDRS appears to distinguish different parkinsonian conditions | Q43923066 | ||
| Cognitive function and regional cerebral blood flow in Parkinson's disease | Q43941726 | ||
| Parametric mapping of [18F]FPCIT binding in early stage Parkinson's disease: a PET study. | Q44060460 | ||
| Comparison of striatal dopamine D2 receptors in Parkinson's disease and progressive supranuclear palsy patients using [123I] iodobenzofuran single-photon emission computed tomography. | Q44179661 | ||
| The feasibility of statistical parametric mapping for the analysis of positron emission tomography studies using 11C-2-beta-carbomethoxy-3-beta-(4-fluorophenyl)-tropane in patients with movement disorders | Q44201982 | ||
| A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study | Q44252121 | ||
| Extrastriatal dopamine D(2) receptors in Parkinson's disease: a longitudinal study | Q44455086 | ||
| Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study | Q44499883 | ||
| Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia | Q44710381 | ||
| Neural basis for impaired time reproduction in Parkinson's disease: an fMRI study | Q44738210 | ||
| Dopamine D2 Receptor Imaging with SPECT: Studies in Different Neuropsychiatric Disorders | Q45292482 | ||
| Regional cerebral blood flow difference between dementia with Lewy bodies and AD. | Q48147926 | ||
| Regional cerebral blood flow in Parkinson's disease with and without dementia | Q48167210 | ||
| Imaging of D2 dopamine receptors of patients with Parkinson's disease using single photon emission computed tomography and iodobenzamide I 123. | Q48290415 | ||
| Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry | Q48470080 | ||
| [123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy | Q48586216 | ||
| Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease: a comparative study using positron emission tomography | Q48590317 | ||
| A comparison of (99m)Tc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer's disease using statistical parametric mapping. | Q48621716 | ||
| In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias | Q48625392 | ||
| An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease | Q49021986 | ||
| [123I]beta-CIT and SPECT in essential tremor and Parkinson's disease. | Q51477232 | ||
| Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. | Q53340013 | ||
| Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson's disease. | Q53928095 | ||
| Early differential diagnosis of Parkinson's disease with 18F-fluorodeoxyglucose and positron emission tomography. | Q54159517 | ||
| P433 | issue | 3 | |
| P921 | main subject | Parkinson's disease | Q11085 |
| dementia | Q83030 | ||
| P304 | page(s) | 158-163 | |
| P577 | publication date | 2004-09-01 | |
| P1433 | published in | Journal of Geriatric Psychiatry and Neurology | Q6295256 |
| P1476 | title | Functional imaging in Parkinson's disease and dementia with Lewy bodies | |
| P478 | volume | 17 |
| Q38152390 | A comparison of FDG-PET and blood flow SPECT in the diagnosis of neurodegenerative dementias: a systematic review |
| Q31033082 | Advances in PET Imaging of Degenerative, Cerebrovascular, and Traumatic Causes of Dementia |
| Q35194993 | Cerebral correlates of psychotic syndromes in neurodegenerative diseases |
| Q36475090 | Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story |
| Q36806669 | Clinical trials in Parkinson's disease dementia and dementia with Lewy bodies |
| Q48785723 | Commentary: DLB and PDD: the same or different? Is there a debate? |
| Q50703533 | Concordance between (99m)Tc-ECD SPECT and 18F-FDG PET interpretations in patients with cognitive disorders diagnosed according to NIA-AA criteria. |
| Q38264846 | Dementia in older people: an update |
| Q60617957 | FDG-PET in Dementia |
| Q40736622 | Is there a preference for PET or SPECT brain imaging in diagnosing dementia? The views of people with dementia, carers, and healthy controls. |
| Q35910290 | Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders |
| Q43954098 | Spectroscopic changes associated with mild cognitive impairment and dementia in Parkinson's disease |
Search more.